Avenue Therapeutics to Present at H.C. Wainwright Neuro Perspectives Conference

Avenue Therapeutics, headquartered in Miami, Florida, is at the forefront of developing and commercializing innovative treatments for neurologic diseases. The company, listed on Nasdaq under the ticker ATXI, is making strides with its key assets, designed to address various central nervous system (CNS) disorders.

On June 20, 2024, Avenue Therapeutics announced that its CEO, Dr. Alexandra MacLean, will be presenting at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. This presentation will be accessible to registered participants starting June 27, 2024, at 7:00 a.m. ET and will be available for on-demand viewing.

Avenue Therapeutics is currently advancing three primary therapeutic candidates. The first asset, AJ201, is a pioneering treatment for spinal and bulbar muscular atrophy. This disease-modifying drug aims to provide significant clinical benefits for conditions that currently have limited treatment options.

The second asset, BAER-101, is an oral small molecule that acts as a selective GABAA α2, α3 receptor positive allosteric modulator. This compound is being developed for treating a range of CNS diseases, potentially offering new therapeutic avenues for patients with debilitating neurological conditions.

The third asset, IV tramadol, is being developed for the management of acute post-operative pain in adults. Currently in Phase 3 clinical development, this intravenous formulation of tramadol is designed for use in medically supervised healthcare settings, addressing a critical need for effective pain management solutions.

Founded by Fortress Biotech, Inc., another company listed on Nasdaq (under the ticker FBIO), Avenue Therapeutics has positioned itself as a leader in the niche market of neurologic disease therapies. The company's focus on innovative and targeted treatments highlights its commitment to improving patient outcomes in areas with significant unmet medical needs.

The upcoming presentation at the Neuro Perspectives Virtual Conference is an important opportunity for Avenue Therapeutics to showcase its advancements and engage with the scientific and investor communities. This event underscores the company's ongoing efforts to bring novel therapies to market and its role in the evolving landscape of neurologic disease treatment.